Date: 2015-02-09
Type of information: Opening of new premises
Compound: facility in Bothell
Company: Juno Therapeutics (USA - WA)
Therapeutic area: Cancer - Oncology
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On February 9, 2015, Juno Therapeutics announced that it has entered into a lease agreement for a facility in Bothell, Washington to manufacture the company's cell therapy products. The facility, which is expected to come online in early 2016, will support Juno\'s planned JCAR015 multicenter clinical trial, additional clinical programs in Juno\'s pipeline, and the company\'s first commercial products. Juno will continue to work with its existing contract manufacturing partners to augment its manufacturing capabilities. Among other advantages, this will enhance flexibility, provide redundancy, and increase capacity in a cost effective manner. Last November, the FDA has granted Breakthrough Therapy Designation to the company's JCAR015 chimeric antigen receptor product candidate.
Financial terms:
Latest news:
Is general: Yes
